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Available online 17 November 2015Background: Friedreich's ataxia (FRDA), a recessive neurodegenerative disorder commonly associated with hy-
pertrophic cardiomyopathy, is caused by silencing of the frataxin (FXN) gene encoding themitochondrial protein
involved in iron–sulfur cluster biosynthesis.
Methods: Application of our previously established FRDA human induced pluripotent stem cell (hiPSC) derived
cardiomyocytes model as a platform to assess the efﬁcacy of treatment with either the antioxidant coenzyme
Q10 analog, idebenone (IDE) or the iron chelator, deferiprone (DFP), which are both under clinical trial.
Results: DFP was able to more signiﬁcantly suppress synthesis of reactive oxygen species (ROS) than IDE at the
dosages of 25 μM and 10 nM respectively which agreed with the reduced rate of intracellular accumulation of
iron by DFP treatment from 25 to 50 μM. With regard to cardiac electrical-contraction (EC) coupling function,
decay velocity of calcium handling kinetics in FRDA-hiPSC-cardiomyocytes was signiﬁcantly improved by DFP
treatment but not by IDE. Furthermechanistic studies revealed that DFP also modulated iron induced mitochon-
drial stress as reﬂected by mitochondria network disorganization and decline level of respiratory chain protein,
succinate dehydrogenase (CxII) and cytochrome c oxidase (COXIV). In addition, iron-response protein (IRP-1)
regulatory loop was overridden by DFP as reﬂected by resumed level of ferritin (FTH) back to basal level and
the attenuated transferrin receptor (TSFR) mRNA level suppression thereby reducing further iron uptake.
Conclusions: DFP modulated iron homeostasis in FRDA-hiPSC-cardiomyocytes and effectively relieved stress-
stimulation related to cardiomyopathy. The resuming of redox condition led to the signiﬁcantly improved cardiac
prime events, cardiac electrical-coupling during contraction.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Deferiprone1. Introduction
Friedreich's ataxia is the most common hereditary ataxia encoun-
tered in clinical practice. While the disease is well known for its neuro-
logical involvements such as progressive gait and limb ataxia [1,2], most
affected individuals died prematurely due to Friedreich's ataxia related
cardiomyopathy [3]. To date, no therapeutic intervention has been
shown to effectively modify or alleviate the pathophysiological process.e reliability and freedom from
ion.
ck, University Department of
University of Hong Kong, 21,
land Ltd. This is an open access articlThe disease is caused by GAA triplet codon expansionwithin theﬁrst in-
tron of the frataxin (FXN) gene encoding the mitochondrial protein,
frataxin, leading to heterochromatin-mediated silencing of FXN in af-
fected individuals [4,5]. While controversial, it is commonly accepted
that frataxin plays an important role in mitochondrial iron metabolism
particularly in the biosynthesis of iron–sulfur cluster, an essential com-
ponent of Complex I–III enzymes in respiratory electronic transport
chain. As such therapeutic strategies have been developed primarily
targeting the increased reactive oxygen species (ROS) [6–9] to possibly
resume the impaired energy generation related to these pathways. For
instance, idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-
1,4-benzoquinone), a structural analog of co-enzyme Q10, shuttling
electrons from Complex I and II and other ﬂavoprotein dehydrogenase
to Complex III of the mitochondrial respiratory chain [10,11] as well as
acting an ROS scavengers, [12] have been demonstrated protectivee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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subsequent clinical trials have failed to demonstrate the efﬁcacy of
idebenone in Friedreich's ataxia patients with any meaningful clinical
beneﬁt of the therapy [13], thus raising the possibility whether the
increased oxidative stress and the impaired ATP production are the
key pathological mechanisms to the clinical phenotypes or just an epi-
phenomenon. In fact, this could also be related to the lack of an
appropriate-yet-reliable disease model that could be recapitulating the
pathophysiological process and allowing functional validation of candi-
date drugs. Using human induced pluripotent stem cells (hiPSCs) derived
cardiomyocytes generated frompatientswith Friedreich's ataxia,wehave
previously reported that the enhanced iron uptake via upregulated trans-
ferrin receptor 1 and the resultant iron accumulation has a key patho-
physiological role to induce downstream cardiomyopathic changes such
as the reduced ATP synthesis, the increased reactive oxidative species
(ROS) production, and the impaired calcium handling properties [14].
Based on our previous ﬁndings, we hypothesize that iron chelating
could be one of the alternatives for treatment of FRDA by modulation of
iron homeostasis. The orally active, iron chelating drug, deferiprone
(DFP, 1, 2 dimethyl-3-hydroxy-pyrid-4-one) and its derivatives were pri-
marily designed and screened for the treatment of iron overload and tox-
icity conditions [15]. They were identiﬁed as powerful free radical
damage inhibitor since 30 years ago [16] and many in vitro, in vivo and
clinical studies have conﬁrmed these results [17,18]. Nevertheless, the
studies of DFP and its derivatives were limited in neuroprotective effects
[19].
In the present study, we exploited our previously established hiPSC-
cardiomyocyte based Friedreich's ataxia model as a drug-testing plat-
form to compare relative efﬁcacy of the antioxidant, idebenone (IDE),
Co-enzyme Q10 analog and an iron chelator, deferiprone (DFP), on mi-
tochondrial function, reactive oxidative species production and calcium
handling properties. Our results not only provide pathophysiological in-
sights to therapeutic strategy for treatment of Friedreich's ataxia related
cardiomyopathy, but also more importantly our approach illustrates
that hiPSC-based drug testing strategy can be an integral part of future
pre-clinical drug development.
2. Methods
2.1. Generation of human induced pluripotent stem cells and their cardiac
derivatives
Skin biopsies were obtained under standard aseptic technique from
a patient with Friedreich ataxia and documented GAA triplet repeat ex-
pansions within the ﬁrst intron of the FXN gene and one healthy age-
and sex-matched control subject. Detailedmethods on hiPSC generation
and characterization, and in vitro cardiac differentiation have been pre-
viously reported [14,20–22].
2.2. Cardiac differentiation
To induce cardiac differentiation, undifferentiated hiPSCs were
maintained in mTeSR™1 medium (STEMCELL Technologies Inc., Van-
couver, BC, Canada) as previously described [23–25]. Four days prior
to induction, hiPSCs were dissociated into single cells with accutase
(Invitrogen, CA, USA) and then seeded onto 12-well matrigel-coated
plate (Thermos Scientiﬁc Inc., Walham, MA, USA) supplemented with
Y27632 (5 μM) (Stemgent, Cambridge, MA, USA). On the ﬁrst induction
day, the culture medium was switched to RPMI medium (Life Technol-
ogies, Maryland, USA)without insulin and supplementedwith B27 (Life
Technologies, Maryland, USA) and a GSK-β inhibitor, CHIR99021
(12 μM) (Selleckchem, Houston, TX, USA), which was refreshed 24 h
later. On Day 4, a Wnt signaling inhibitor, IWP2 (5 μM) (Selleckchem,
Houston, TX, USA), was added to the culturemedium. Typically, sponta-
neously beating cardiomyocytes could be observed around 9 days after
induction. The cells were maintained in the culture and weredissociated approximately 30 days after induction using 0.25%
Trypsin-EDTA for further experiments.
2.3. Friedreich's ataxia related cardiomyopathy model
To recapitulate the cellular features of Friedreich ataxia
cardiomyocytes, hiPSC-derived cardiomyocytes were cultured for 48 h
in a medium supplemented with 200 μM iron (II) sulfate as previously
described [14]. Iron content of hiPSC-derived cardiomyocytes was
assayed with rate ﬂuorescence quenching of calcein by iron. The disso-
ciated cardiomyocytes from iPSCs were plated onto a 96-well white
microtiter plate. Calcein-AM (Life Technolgies, Maryland, USA)was dis-
solved in DMSO with a stock concentration of 10 mM. The dissociated
cardiomyocytes were incubated in 10 μM calcein-AM in 5% FBS
cardiomyocytes maintenance medium for 15 min, and washed twice
with fresh medium before recording by M200 plate-reader (Tecan,
Männedorf, Switzerland) for every 5 min. The intracellular iron (II)
ion levels were expressed as reciprocal of the initial rate of ﬂuorescence
intensity rise.
2.4. Drug testing
To test the potential therapeutic effects, idebenone (Sigma-Aldrich,
St. Louis, MO) and deferiprone (Selleckchem, Houston, TX, USA) were
dissolved in DMSO at stock concentration 50 mM, stored at −20 °C,
andwere freshly diluted to the test concentration according to previous
viability testing [6].
2.5. Reactive oxygen species (ROS) assay
hiPSC-derived cardiomyocytes treated with iron (II) sulfate for 48 h
were seeded into a 96-well blackmicrotiter plate at a density of 2 × 104/
well. The ROS contents in hiPSC-derived cardiomyocytes were deter-
mined using DCFDA Cellular ROS Detection Assay Kit (Abcam, Cam-
bridge, UK) according to manufacturer instructions. Brieﬂy, hiPSC-
derived cardiomyocytes were washed with DPBS and incubated with
25 μM DCFDA mix for 45 min at 37 °C in dark. Cells were then washed
once with buffer solution before drug treatment. The signal was then
detected every 5 min by M200 plate-reader (Tecan, Männedorf,
Switzerland) with excitation wavelength at 485 nm and emission at
535 nm. Columns of non-stained cells were reserved as blank control.
2.6. Measurement of intracellular calcium homeostasis
Cytosolic calcium transients weremeasured in isolated hiPSC-derived
cardiomyocytes using a confocal imaging system (Olympus FluoviewSys-
tem version 4.2 FV300 TIEMPO) mounted on an upright Olympus micro-
scope (IX71) as previously described as previously described [24,26–28].
Brieﬂy, cells were loaded with 1:1 (v/v) amount of 20% Pluronic®-F127
(Invitrogen, life technologies) and 5 μM Fluo-3 AM (Sigma-Aldrich, St.
Louis, MO) dissolved in DMSO with stock concentration of 5 mM for
45 min at 37 °C in Tyrode solution containing 140 mM NaCl, 5 mMKCl,
1 mMMgCl2, 1.8 mM CaCl2, 10 mM glucose and 10 mM HEPES at pH
7.4. Calcium transients of single cardiomyocytes were recorded with a
temporal resolution of the line scan at 274 frames per second. All confocal
calcium imaging experiments were performed within 48 h after isolation
in order to minimize contamination of time-dependent changes in calci-
um handling property in culture. Fluorescence intensity was recorded
by area against time mode (XYT) as a line plot, the calibration curve
showed that there is linear relationshipbetweenﬂuo-3 intensity recorded
with calcium concentration up to 630 nM [Ca2+]. The data were then
quantiﬁed as the background subtracted ﬂuorescence intensity changes
normalized to the background subtracted baseline ﬂuorescence using
Image J (National Institutes of Health. Amplitudes, maximal upstroke
anddecay velocity of calcium transientwere analyzed byClampﬁt version
9.2.0.09. (Axon Instruments, Inc., Foster City, CA).
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The dissociated cardiomyocyteswere seeded onto 2mmglass cover-
slip and incubated for 48 h. Staining of mitochondria was revealed by
adding 10 μM of mitoROS (Molecular probes) dissolved in DMSO in
HBSS buffer containing 1% FBS. The cells were further stained for
15min at 37 °C and 5% CO2. Brieﬂy, washed the cells with HBSS staining
buffer and ﬁxed the cells in 4% paraformaldehyde. The cells were then
mounted onto Flurosave hydrophilic mountant (Merck Millipores, Bil-
lerica, MA, USA) after staining with DAPI.2.8. Immunoblotting of mitochondrial protein and ferritin
Mitochondrial fractionwas prepared by kit from abcam (Cambridge,
MA). In brief, the freezed cell pellet with one million of cardiomycoytes
was lysed by Doune's homogenizer for 20 strokes in 0.5 mL reagent A.
The lysate was spinned with 100 g for 5 min while the supernatant
was collected. The remaining pellet that was lysed again in reagent B
is further subjected to spinning.
Regarding thewhole cell lysis, the cells werewashedwithDPBS, and
collected in RIPA buffer (Cell Signaling Technology, Danvers, MA) con-
taining 0.2% Triton X-100, 5mMEDTA, 1mMPMSF, 10 μg/mL leupeptin,
10 μg/mL aprotinin, with additional 100mMNaF and 2mMNa3VO4 and
lysed for 30min on ice. The supernatant was collected after spinning for
20min at 12,000 g. Protein assaywasperformed using a Bio-Rad protein
assay kit (Hercules, CA).
Five microgram of resultant protein lysate was loaded into Bolt® 4–
12% Bis-Tris plus gel (Gibco) andwere transfer by transblot system onto
nitrocellulose membranes and blocked with 5% non-fat dry milk in TBS
[pH 7.4] with 0.5% Tween-20 at 4 °C. The transferred protein will be
probed by primary mouse monoclonal antibodies to ﬂavoprotein (FP)
subunit of succinate dehydrogenase (SDH) (CxII or SDHA) (Cat no:
ab14715; Abcam, Cambridge, UK, 1:2000) and rabbit polyclonal anti-
bodies against (COXIV) (Cat no: ab16056; Abcam, Cambridge, UK,
1:5000) as a mitochondrial loading control and were further visualized
by secondary HRP antibodies (Cell Signaling Technology, Danvers, MA;
1:2000).2.9. Reverse transcription quantitative polymerase chain reaction (RT-
qPCR)
Total RNA from hiPSC-cardiomyocytes was extracted with TRI regent
(Life Technologies). Reverse transcription was then performed using
1 μg RNA in a ﬁnal volume of 20 μL, using QuantiTect® reverse transcrip-
tion kit (Qiagen, Hilden, Germany, http://www1.qiagen.com) according
to the manufacturer's instructions. Quantitative PCR analysis was per-
formedwith real-time PCR system (StepOne Plus Reall Time PCR systems,
Applied Biosystems) using the Fast SYBR Green Reagent (Qiagen). For
ampliﬁcation, after initial holds for 5 min at 95 °C, 40 cycles of 95 °C for
30 s followed by corresponding annealing temperature for 30 s and 72 °C
for 30 s, melt curve analysis was performed. The relative quantiﬁcation of
PCR products was performed according to the 2−ΔΔCt method, using
mouse GAPDH as internal control. Where ΔΔCt = [(Ct target gene - Ct
GAPDH) Treatment group -(Ct target gene - Ct GAPDH) Control group]].2.10. Statistical analysis
All graphs were prepared using GraphPad Prism™ 5. Results were
expressed as mean ± SEM. Means of two populations were compared
using Student's t-test for paired observations. Two way analysis of var-
iance (ANOVA) was performed followed by Holm–Sidak test for all
pairwise multiple comparison procedures, using SPSS (version 14.0). A
value of p b 0.05 was considered signiﬁcantly different.2.11. Study approval
The study protocol of procurement of human tissue for the genera-
tion of hiPSCswas approved by the local Institutional ReviewBoardUni-
versity of Hong Kong/Hospital Authority Hong Kong West Cluster
(HKU/HA HKW IRB; UW08-258) and was registered at the Clinical
Trial Center, the University of Hong Kong (HKCTR-725, http://www.
hkclinicaltrials.com). Voluntary prior informed consents were obtained
from all participants.
3. Results
In the current study, we aimed to compare the effect of DFP and IDE
on FRDA-hiPSC-cardiomyocytes using ROS assay and cardiac functional
changes in terms of calciumhandling properties. Next, we further inves-
tigated the mechanism of DFP in treatment of FRDA in the scope of mi-
tochondrial response, iron homeostasis gene regulation and labile iron
accumulation.
3.1. ROS synthesis and intracellular iron accumulation were signiﬁcantly
suppressed by DFP
Since the major deleterious effect to mitochondrial energy syn-
thesis dynamics is affected by redox imbalance, we aimed to under-
stand the extent of improvement in ROS synthesis from FRDA-hiPSC
cardiomyocytes under iron stress using 2′,7′ –dichloroﬂuorescin
diacetate (DCFDA) Cellular ROS Detection Assay. ROS assay is a golden
standard to access redox status of a cell, in present study, we ﬁrst did
pilot study with the test concentrations of iron chelater, deferiprone
(DFP), ranged from 25 to 50 μM, while the dosages of Co-enzyme Q10,
idenbenone, were tested from 0.01 to 10 nM in log10 scale [6]. In
basal condition, supplementation of iron (II) sulfate at 100 μM and
200 μMwould raise the amount of ROS synthesis dose-dependently in
both WT-and FRDA cells, while FRDA cells showed a more prominent
surge in ROS synthesis for 32% and 65% in 100 μM and 200 μM Fe2+ in
comparison with basal condition. In basal condition, both of the wild
type and FRDA-hiPSC-cardiomyocytes are responsive to treatment of
DFP at the minimal dose tested at 25 μM and presented with a signiﬁ-
cant suppression of ROS production (Fig. 1A). In presence of exogenous
iron (II) loading at 100 to 200 μM, theWT-cell lines are slightly respon-
sive to idebenone in both levels of iron loading stress while FRDA-
hiPSC-cardiomyocytes did not show any response to every dose of
idebenone (Fig. 1B). On the contrary, DFP is able to exert a higher efﬁca-
cy on suppression of ROS synthesis ranged from a minimal dose of
25 μM to 50 μM in both of the WT- and FRDA-hiPSC-cardiomyocytes.
In the FRDA cells, the amount of ROS production was signiﬁcantly re-
duced by about 52%, 62% and 60% by all dosages of DFP treated in con-
trol, 100 μM and 200 μM Fe2+ loaded group respectively (Fig. 1A)
(n = 3, *p b 0.005; FA: basal vs. 25 μM DFP co-treatment with 100 μM
Fe2+: 132 ± 12% to 50 ± 9%**; basal vs. 25 μM DFP co-treatment with
200 Fe2+: 165 ± 14 to 70 ± 7%**).
Since the stress was primarily due to oxidation of iron accumulated
as a result of FXNdeﬁciency, which plays a role in the altered iron-sulfur
cluster synthesis pathway, we sought to focus on the extent of intracel-
lular iron accumulation. A ﬂuorescence based assay using calcein-AM
dye was performed to access rate of iron accumulation in terms of
bleaching of signal per minute. In baseline condition, iron accumulation
rate was similar between WT-and FRDA-hiPSC-cardiomyocytes (Fig.
1C). However, iron loading for 48 h signiﬁcantly increased the rate of
iron accumulation in FRDA-hiPSC-cardiomyocytes for 33% (from basal
0.003 ± 0.000 to Fe-loaded condition 0.004 ± 0.000 FLU/min**, n =
6, **p b 0.005) and the rate of accumulation in FRDA cells is also remark-
ably elevated for 14.4% in comparison withWT cells (200 μM Fe2+:WT
vs FRDA: 0.003 ± 0.000 vs. 0.004± 0.000 FLU/min, n = 6, **p b 0.005).
Consistent with our ROS assay result, DFP treatment at the lowest dose
(25 μM) started to signiﬁcantly suppress the rate of iron accumulation
Fig. 1.Reactive oxygen species (ROS) assay on the effect of (A)Deferiprone (DFP) and (B) Idebenone (IDE) on Fe2+ (200 μM)overloadedWT- and FRDA-hiPSC-cardiomyocytes. DFP is able
to exert a high efﬁcacy on suppression of ROS synthesis that ranged from aminimal dose of 25 μM to 50 μM in both of theWT- and FRDA-hiPSC-cardiomyocytes (n= 3, Control vs. 100 or
200 μM Fe2+, ##p b 0.005, ###p b 0.01; Baseline vs. DFP or IDE treatment, *p b 0.05, **p b 0.01 and ****p b 0.005). (C) Rate of Iron uptake assay by calcein ﬂuorescence bleaching in DFP-
treated hiPSC-cardiomyocytes Iron overload in FRDA-iPSC cardiomyocytes. The level of intracellular iron (II) ions content is inversely proportional to the signal of the ﬂuorescence dye,
calcein-AM, since high amount of divalent iron ions will quench the ﬂuorescence signal. The rate of intracellular iron accumulation is calculated by 1/ﬂuorescence signal of calcein (1/
FLU/min). Iron loading in FRDA-iPSC-CMC is signiﬁcantly higher when it is treated with extreme amount of Fe2+ (200 μM) (n = 6; baseline vs drug treatment: **p b 0.005 and ***p b
0.001; WT vs. FA with Fe2+ loading (200 μM; n = 6; #p b 0.05). DFP is able to signiﬁcantly suppress intracellular iron (II) level.
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Fe2+ + 25 μM DFP: 0.004 ± 0.000 to 0.003 ± 0.000 (n = 6; **p b
0.01), and interestingly, the extent of reduction is in a dose-dependent
manner up to 50 μM of DFP, which indicates such method is a sensitive
assay to detect early event sign of stress. DFP is able to chelate the iron
successfully in a remarkable manner.3.2. Calcium handling of DFR treated improved calcium reuptake function
Regarding calcium handling properties of the FRDA-hiPSC-
cardiomyocytes, which account for electrical-contraction function, the
effect of deferiprone and idebenone was compared to evaluate the
treatment efﬁcacy to excitation-contraction (EC)-coupling process,
which is highly energy demanding. The dosages of DFP at 25 μM and
IDE at 10 nMandwere selected for treatment of cardiomyocytes for cal-
cium handling studies based on the dose responses to reduce ROS syn-
thesis. Consistent with our previous studies, the upstroke and decay
kinetics of FRDA-hiPSC-cardiomyocytes was signiﬁcantly retarded in
presence of iron stress (Fig. 2C and D). In WT-hiPSC-cardiomyocytes,
IDE did not rescue calcium kinetics upon iron stress in terms of decay
velocity (WT: Fe2+ vs. Fe 2+ + IDE: −0.008 ± 0.001 vs. −0.008 ±
0.001 F/Fo/s) (Fig. 2D). The upstroke velocity of IDE treated cell
was even retarded in presence of IDE treatment of WT cells (WT: Fe2+
vs. Fe 2++ IDE: 0.029± 0.002 vs. 0.017± 0.001 F/Fo/s). On the contrary,
the decay kinetics of FA-hiPSC-cardiomyocytes with DFP treatment was
signiﬁcantly better than iron stressed conditiondespite remarkable differ-
ence was observed in wild type cell lines (FRDA: Fe2+ vs. Fe 2+ + DFP:
−0.004 ± 0.000 vs.−0.005 ± 0.000F/Fo/s, n = 13, *p b 0.05) (Fig. 2D.
And the unaltered level of sarcoplasmic reticulum calcium ATPase
(SERCA) gene expression in the presence of iron or DFP showed thatthe compromised calciumdecay kinetics is solely due to suppressed ener-
gy (Fig. 4C).
3.3. DFP relieved mitochondrial stress in terms of organization and respira-
tory chain protein expression in FRDA-hiPSC-cardiomyocytes
With the evidence of drug screening results from ROS synthesis
and cardiac functional assay, we focused on testing of the effect of
DFP in terms of mitochondrial properties which is highly vulnerable
to oxidative stress. This was evaluated by studying the physical orga-
nization of mitochondrial network in the WT- or FRDA-hiPSC-
cardiomyocytes visualized by mitoROS staining. In basal condition,
both of the cell lines showed a well-organized network of mitochon-
dria (Fig. 3A). Nevertheless, a sign of stress was observed in FRDA-
hiPSC-cardiomyocytes when they were undergone Fe (II) stress. A
prominent disorganized and fragmented mitochondrial network as
well as depleted amount of mitochondria were observed (arrows;
Fig. 3A).
To speciﬁcally evaluate iron-sulfur cluster containing respiratory
protein level, mitochrondrial proteinwas extracted byDounce's homog-
enization followed by imunoblotting (Fig. 3B). Succinate dehydroge-
nase (CxII) was investigated because our previous study reported that
succinate-dependent ATP synthesis is vulnerable to iron loading in
FRDA-hiPSC-cardiomyocytes while cytochrome c oxidase or complex
IV (COXIV) is served as a marker to evaluate intact mitochondria [14].
Prominent reduction of respiratory chain protein levels in CxII isolated
frommitochondrial fraction revealed the iron load condition destroyed
mitochondrial content in both WT- and FRDA-hiPSC cardiomyocytes.
Corresponding reduction in COXIV level presented in whole cell lysate
implied a reduced amount ofmitochondria upon stress condition. Inter-
estingly, the level of CXIIwas dose-dependently resumed byDFP ranged
Fig. 2. Functional properties in the iron-loaded FRDA-iPSC-cardiomyocytes. (A) Representative tracing of calcium transients inWT-and FRDA-iPSC-cardiomycyteswith DFP (25 μM) or IDE
(10 nM) in presence of iron (II) loading; (B) Themaximum calcium released (amplitude), (C) Vmax upstroke and (D) decay velocity (F/Fo/ms) (*p b 0.05, **p b .005 and ***p b 0.0001;WT
vs. FRDA in every group of treatment or otherwise indicated by arrows) from 20 to 40 samples were presented. The iron-overloaded FRDA-iPSC-CMC presented a suppressed rate of cal-
cium release and uptake.
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tion. In bothWT and FA cells, cytosolic levels of ferritin (FTH1), a detox-
iﬁcation protein as an indicator of intracellular iron level, were surge inFig. 3. Mitochondrial responses to DFP treatment of FRDA-hiPSC-CMC. (A) Sign of stress wa
overloadedwith iron. (B) Immunoblot showing Fe2+ overload induced down regulation of resp
protein, cytochrome c oxidase (COX IV) in mitochondrial fraction (mito) and whole cell lysat
Whole cell level of Ferritin (FTH1) was declinedwith treatment of DFP under iron-overload con
with DFP for 24 h the dosages ranged from 25 to 50 μM. The protein lysatewas prepared bymito
The COX4 would be served as a normalization control of mitochondria abundance in the cell sthe presence of iron loading. Both dosages of DFP reduced level of ferri-
tin in spite of iron overload condition, the detoxiﬁcation action exerted
by FTH1 may no longer be necessary.s indicated by fragmented organization of mitochondria network of FRDA-hiPSC-CMC
iratory chain protein, succinate dehydrogenase (SDHA) CXII andmitochondrialmembrane
e could be resumed by DFP treatment dose-dependently in FRDA-hiPSC-cardiomyocytes.
dition. The cells were stressed by preloadedwith Fe2+ (200 μM) for 48 h before treatment
chondrial fractionation or fromwhole cell with 5 μg loaded into each lane of the 4–20% gel.
ince FRDA only affect Complex I, II and III synthesis in the respiratory transport chain.
969Y.-K. Lee et al. / International Journal of Cardiology 203 (2016) 964–9713.4. Gene regulation of frataxin (FXN), transferrin receptor (TSFR), sarco-
plasmic reticulum calcium ATPase (SERCA) and iron homeostasis protein,
and mitochondrial carrier protein ¾ (MRSC3/4)
Frataxin gene expression signiﬁcantly silenced in FRDA-hiPSC-
cardiomyocytes was independent to Fe2+ stimulation (Fig. 4A). When it
comes to iron homeostasis, transferrin receptor (TSFR), the transferrin-
bound iron transporter, was suppressed in response to iron loading and
FRDA-hiPSC-cardiomyocytes were less responsive to the regulated sup-
pressed TSFR gene expression level which is consistent with our previous
ﬁndings (Fig. 4B). Interestingly, DFP is able to slightly relieve the level of
suppressionpossibly due tomaintenance of lower intracellular Fe2+ load-
ing by the chelator. Surprisingly, in both cell lines, the mitochondrial car-
rier proteins (MRS3/4), which governmitochondrial uptake of Fe2+ from
cytosol to mitochondrial region for synthesis of Fe–S cluster, were elevat-
ed in the presence of iron load (WT: CTR vs. Fe2+: 0.863 ± 0.06 vs.
1.132 ± 0.197*; FA: CTR vs. Fe2+: 0.813 ± 0.070 vs. 1.188 ± 0.197-fold
of gene expression ofWT-hiPSC-CMC; n=5, *p b 0.05) (Fig. 4D)meaning
that the iron was kept loading into mitochondrial compartment though
there is reduced amount of trasferrin bound iron uptake from extracellu-
lar region into cytosol. Mitochondrial iron loading may not be relevant to
extracellular iron abundance, but is possibly related to intracellular iron
accumulated levels as indicated in the above data shown in calcein ﬂuo-
rescence bleaching assay (Fig. 1C). FRDA cells tended to accumulate
more intracellular iron but the mitochondrial iron amount remains un-
known in the current study. We could not observe obvious change with
mitochondrial iron transporter gene expression between WT-and FRDA
cells upon iron loading.
4. Discussion
To address the iron misdistribution with enhanced iron concentra-
tions in mitochondria and relative cytosolic labile iron depletion, the
use of membrane-permeable iron chelators, for example, deferiprone,
has been considered [29,30]. This drug has been widely used for oralFig. 4. (A) Iron loadingdoesnot alter geneexpression of frataxin (FXN) and (C) calciumhandling
receptor (TSFR) and (D) elevation of themitochondrial carrier protein (MRS3/4). DFP treatment
ilar tendency inWT group aswell (FRDA: Fe2+ vs. Fe2++DFP, *p b 0.05, n= 3). qPCR determin
baseline of each cell line or otherwise indicated with arrows, was signiﬁcantly reduced upon irprescription of the treatment of beta-thalassemia [31–35]. Deferiprone
was tested in a pilot, open-label study and in a randomized, placebo-
controlled phase II clinical trial. Although in the pilot study deferiprone
reduced anMRI signal indicating iron overload, the phase II study failed
to demonstrate an improvement of ataxia,whichwas evenworsened by
high doses of the drug. However, deferiprone was able to reduce heart
hypertrophy at all tested doses [30,35].
Iron-overload cardiomyopathymediated by Fredriech's ataxia is one
of the major causes of heart failure as a consequence of diastolic dys-
function, increased arrhythmic risk and late stage dilated cardiomyopa-
thy [5]. Such iron-induced oxidative damage in disease condition has
been linked to increased cardiomyocytes loss due to apoptosis and al-
tered cellular metabolism. The iron-mediated stimulation of cardiac ﬁ-
brosis would also lead to abnormal impulses conduction. Current
therapeutic approaches to treat FRDA have become utmost crucial
which mainly include: 1) Strategies to increase frataxin mRNA expres-
sion by decreasing heterochromatin formation at the GAA repeat to
counteract gene silencing [5,36–38]; 2) methods to chelate iron and
thereby reduce associated oxidative stress [39,40]; 3) to use antioxida-
tive reagent that reduces ROS stress (36).
By taking advantages of our experience in utilization of FRDA-iPSC-
cardiomyocytes model that recapitulated cardiomyopathy phenotypes
in iron overload condition [14], in our current study, we successfully
established a drug screening platform to identify potential candidates
that ensure proper functioning of mitochondria so as to maintain nor-
mal heart function. Gene manipulation strategy was not preferable for
clinical application because of the labor intensive protocol and potential
safety issue concerning off target activities or viral gene transfer. There-
fore, the iron chelator, derferiprone (DFP), was chosen as one of the po-
tential agents for FRDA treatment because the disease mechanism was
proposed as dependent on iron homeostasis as previously described
[14]. Lastly, we also tested the effect of Co enzyme Q10, idenbenone
(IDE), as a antioxidative strategies to relieve ROS burden of FRDA cells.
In the present study, iron induced ROS synthesis was more signiﬁ-
cantly suppressed by DFP than IDE in FRDA-hiPSC-cardiomyocytes.protein, SERCA (B) but leads to suppression of crucial iron homeostasis protein, transferrin
signiﬁcantly elevated the depleted TSFR gene expression level in FRDA and showed a sim-
ation of gene level was calculated byΔΔCtmethodwith treatment group comparingwith
on (II) stress in both WT- and FRDA-iPSC-CMCs (n = 3, *p b 0.05 or ***p b 0.005).
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the cell (Fig. 1). Further investigation of FRDA therapy was focus on
the lowest dosage of DFP to relieve ROS level at 25 μM to dissect the de-
tailed mechanism. Since electrical coupling (EC) coupling process is
highly sensitive to redox changes, the beneﬁcial effects of DFP were ex-
trapolated to cardiac function in terms of calcium handling properties
with the upstroke and decay velocity of FRDA cell improved by DFP
(Fig. 2C and D). This implied that SERCA function retarded by iron over-
load could be more efﬁciently resumed by DFP [37].
Indeed, excessive dosages of idebenone were proved to be harmful
to skin ﬁbroblasts of FRDA patients [40–42]. On the contrary, DFP is
able to enhance redistribution of iron to a normal status. IDE only
exerted a weak effect because it is not involved in iron regulation.
Upon severe iron stress or in clinical situation, if the aged patient with
iron accumulated exceeding threshold level, typical cardiomyopathy
or neuron dysfunction would be developed, making the Co-Q10 drug
may no longer work.
With respect to iron homeostasis and mitochondrial responses,
in FRDA condition, loss of frataxin results in the induction of iron accu-
mulation as indicated by our calcein bleaching assay which showed ex-
ogenous iron loading (200 μM) was able to signiﬁcantly induce its
accumulation (Fig. 1C). These results possibly agreed with Pandolfo's
claims that inefﬁcient Fe–S cluster biogenesis in FRDA leads to homeo-
stasis response resembling iron deﬁciency, since the cells sense there
is not enough building blocks for respiratory chain protein synthesis
[30]. In fact apart from that, high ROS level impedes Fe–S cluster synthe-
sis would worsen iron accumulation condition [43]. As a consequence,
unbalanced intracellular distribution of the irons occurs, and iron enter-
ing into cytosol may be directly shuttled into mitochondria, where it
accumulates. Furthermore, slight supplementation of iron may be ben-
eﬁcial to treatment because iron deﬁciency would worsen the disease
progression due to more aggressive uptake of iron by a false signal
sense in disease condition [36,44]. Our results were also agreed with
clinical studies with the cohort of thalassemia patients treated with
oral DFP undergoing less myocardial iron burden and better global sys-
tolic ventricular function comparing with the patients treated with the
other two types of iron chelator oral deferasirox or subcutaneous
desferrioxamine [31,32,35]. This could be explained by the fact that
the iron chelator, DFP, is able to enter mitochondria and redirect iron
to other cell compartment. However, with other kinds of iron chelator
that do not favormembrane permeation, only cytosolic ironwas deplet-
ed that may further boost iron uptake with into mitochondria.
As a consequence of excessive iron uptake in FRDA cell, the excessive
ROS synthesis destroyed mitochrondrial function with disorganized
mitochondrial network by mitoROS staining (Fig. 3A) and depletion
of respiratory chain enzyme CxII and COXIV on the inner membrane
(Fig. 3B) as revealed by the protein immunoblot ofmitochondrial fraction
and whole cell lysate respectively (Fig. 3A and B). The altered level of
COXIV, an internal control of mitochondria, might probably be related
to depletion of mitochondria number within the cardiomyocytes. The
sign of iron overload stress was signiﬁcantly relieved by DFP in a dose de-
pendent manner in the aspect of protein level of respiratory enzyme and
the reduced surge in ferritin (FTH1), the iron detoxiﬁcation protein in cy-
tosol. Such condition might be due to impeded oxidation of ferrous Iron
(Fe2+) derived from labile iron pool oxidation which generate consider-
able amount of hydroxyl radicals [45].
In fact, iron homeostasis is well controlled in a strictly regulated
manner at transcriptional level. A key iron regulator, iron responsive el-
ement binding protein 1 (IRP1), which is localized in cytosol, is also an
iron–sulfur protein. IRP1 and IRP2 predominately regulate ironmetabo-
lism by binding to the iron responsive element (IRE) sequence motif,
which exist in mRNA of proteins involved in iron metabolism [39].
Under physiological conditions, iron transport tightly regulated via neg-
ative feedback mechanism involving transferrin and its receptor and
other iron transportors, with gene expression control downstream of
IRE [5,14]. When intracellular iron level is high, IRP1 incorporates withiron sulfur clusters to interfere the binding of IRP to iron responsive el-
ements, thus preventing further increase in intracellular iron [46,47].
However, in case of frataxin defeats, insufﬁcient Fe–S cluster synthesis
not only lead to attenuated homeostasis response such as IRP1 activa-
tion suppression of transferrin receptor, TSFR (Fig. 4B), but also
increased iron uptake to mitochondrial through MRCS3/4 (Fig. 4D).
However, as presented in our gene expression studies, when intracellu-
lar iron level was restored by DFP with no alternation of FXN level, the
TSFR was signiﬁcantly elevated as a feedback response. Nevertheless,
supplementation of mitochondrial targeting iron chelator, DFP, did not
alter iron stress response of MRS3/4, a putative solute transporter of
the inner mitochondrial membrane. Low dose supplementation of iron
to cytosolic region keeps balance and maximizes residual expression
of frataxin.
5. Conclusion
We have identiﬁed that DFP, the mitochondrial permeable iron che-
lator, is a more effective drug to treat FRDA-mediated cardiomyopathy
by reducing ROS burden and improving calcium handling kinetics in
comparison with IDE. The decreased iron accumulation rate accounts
for the reduced redox burden due to oxidation of iron (II) with corre-
sponding mitochondrial responses. In FRDA condition, lower abun-
dance of mitochondrial protein was found in CMC under iron stress
and DFP is able to resume the respiratory chain protein, CxII and themi-
tochondria level in terms of COXIV. Reduced iron accumulation by DFP
alleviated the suppressed TSFR gene expression. This indicated the
iron homeostasis regulated by IRP-1 is altered by the attenuated nega-
tive feedback mechanism of iron uptake.
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